Progress Scientific Inc.
$72,000.00 CAD
≈ 11 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- April 1, 2018 – April 30, 2019
- Reference
- nrc-cnrc:172-2018-2019-Q1-904073
Published purpose
The Firm is developing a pharmacological therapy using drugs that target the alpha2beta2 subtype of nicotonic acetylcholine receptor to counter respiratory depression associated with opiates (e.g. fentanyl), propofol, alcohol, barbiturates, apnea of prematurity, obstructive and central sleep apnea, brain and spinal cord damage, and genetic disorders affecting breathing (e.g. Pompe Disease). They will perform a systematic series of pre-clinical studies using rodent models to determine the most effective candidate compounds to be tested in early stage clinical trials.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions